Clinical Study
Predictors of Neurological and Functional Recovery in Patients with Moderate to Severe Ischemic Stroke: The EPICA Study
Table 1
Baseline characteristics of study population.
| | Characteristics | |
| | Demographics | | | Age (years) | | | Women | 64 (49.2) | | Married | 83 (64.3) | | Weight (kg) | | | Height (cm) | | | Body mass index (kg/m2) | | | Risk factors | | | Hypertension | 77 (58.8) | | Hyperlipidemia | 53 (40.5) | | Diabetes mellitus | 30 (22.9) | | Atrial fibrillation | 16 (12.2) | | Ischemic heart disease | 12 (9.2) | | Smoking | 36 (27.5) | | Alcohol consumption | 10 (7.6) | | Drug abuse | 4 (3.1) | | Prestudy clinical information | | | Pre-stroke modified Rankin Scale | | | 0 | 113 (86.9) | | 1 | 17 (13.1) | | Stroke onset to arrival in emergency room (hours) | 18.9 (28.6) | | National Institute of health stroke scale at 24 hours from admission | 14.1 (3.8) | | Modified Rankin Scale on admission, (median, IQR) | 4 (3-5) | | Glasgow coma scale on admission | 14.1 (1.9) | | Brain imaging performed | | | Computed tomography | 70 (53.4) | | Magnetic resonance imaging | 61 (46.6) | | Type of lesion | | | Partial anterior circulation infarct (PACI) | 51 (39.5) | | Total anterior circulation infarct (TACI) | 38 (29.5) | | Lacunar infarct (LACI) | 23 (17.8) | | Posterior circulation infarct (POCI) | 17 (13.2) | | Stroke onset to study entry; days | | | Early hyperacute stage (0 to 6 hours) | 6 (4.6) | | Late hyperacute stage (<6 to24hours) | 5 (3.8) | | Acute stage (>24 h to 72 hours) | 12 (9.2) | | Post-acute stage (>3 to 7 days) | 15 (11.5) | | Subacute stage (1 to 3 weeks) | 21 (16.0) | | Chronic stage (>3 weeks) | 72 (55.0) | | Therapies received | | | Revascularization (intravenous thrombolysis, endovascular thrombectomy) | 40 (30.5) | | Medications by class | | | Statin & other lipid-lowering agents | 65 (51.6) | | Antihypertensive | 60 (47.6) | | Betablocker | 20 (15.9) | | Antidiabetic | 20 (15.9) | | Antiplatelet | 55 (43.7) | | Anticoagulant | 40 (31.7) | | Antiulcer | 41 (32.5) | | Antidepressant | 22 (17.5) | | Anxiolytic/sleeping pill | 22 (17.5) | | Analgesic | 8 (6.3) | | Antiarrhythmic | 5 (4.0) | | Antiepileptic | 5 (4.0) | | Rehabilitation | 119 (93.0) | | ≥1 hour daily | 67 (56.8) | | ≥1 hour, 3 times a week, <1 hour daily | 26 (22.0) | | Other | 25 (21.2) | | Dietary supplementation | 60 (45.8) | | MLC901 (NurAiD™) | 59 (45.0) | | Citicoline (Somazina®) | 2 (1.5) |
|
|
Data missing in 5 patients, 3 patients, 1 patient, 2 patients. Unless otherwise stated, summary data are presented as (%) or as . |
